Roche Holding AG RHHBF
490.00 USD -1.13 (-0.23%)
At closeNov 3, 2026, 4:00 PM EST
505.00 Day range 505.00
335.90 52-week range 514.08
- YTD
- +9.96%
- 1 year
- +54.92%
- Market cap
- 390.42B
- EPS (ttm)
- 19.36
- P/E ratio
- 25.31
- YTD return
- +9.96%
- 1-year return
- +54.92%
- Volume
- 40
- Avg volume
- 95
- Open
- 505.00
- Previous close
- 491.13
- Day's range
- 505.00 – 505.00
- 52-week range
- 335.90 – 514.08
- Earnings date
- Jul 23, 2026
2Y +147.77 (+43.04%)
Next earnings
Jul 23, 2026
Expected Jul 23, 2026. Consensus EPS estimate 12.51.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 23, 2026 | Jun 30, 2026 | 12.51 | — | — | — |
| Jan 29, 2026 | Dec 31, 2025 | 10.83 | 10.56 | -0.27 | -2.49% |
| Jul 24, 2025 | Jun 30, 2025 | 13.18 | 5.81 | -7.37 | -55.92% |
| Jan 30, 2025 | Dec 31, 2024 | 9.25 | 2.77 | -6.48 | -70.05% |
| Oct 23, 2024 | Jun 30, 2024 | 10.42 | 8.71 | -1.71 | -16.41% |
| Apr 26, 2024 | Dec 31, 2023 | 10.07 | 6.34 | -3.73 | -37.04% |
News
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs 
Roche: Valuation Leaves Limited Upside 
Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors 
Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration
Your note
Sign in to keep a note on RHHBF — it syncs with the Stock Master app.